Governance models for change control decisions with CMC implications Governance models for change control decisions with CMC implications In the highly regulated pharmaceutical and biotechnology sectors, effective management of post-approval changes (PACs) is crucial. This comprehensive guide delves into the regulations, guidelines, and agency expectations surrounding PACs, specifically under the categories of Post Approval Supplement (PAS), Changes Being Effected in 30 days (CBE-30), and Changes Being Effected Immediately (CBE-0). Understanding how to navigate these paths ensures compliance and helps avoid common pitfalls in the regulatory process. Context Change control in the context of Chemistry, Manufacturing, and Controls (CMC) is essential…

Common FDA Questions on PAS and CBE Submissions and How to Avoid Them Common FDA Questions on PAS and CBE Submissions and How to Avoid Them In the world of pharmaceutical and biotechnology product development, navigating the complexities of regulatory requirements for post-approval changes (PAC) is pivotal for ensuring compliance and maintaining product quality. This article serves as a comprehensive regulatory explainer manual for Kharma and regulatory professionals, focusing on the common questions posed by the FDA regarding Post-Approval Supplements (PAS), Changes Being Effected in 30 Days (CBE-30), and Changes Being Effected Immediately (CBE-0) submissions. We will delve into relevant…

Digital tools to track global post approval change commitments and status Digital tools to track global post approval change commitments and status The evolving landscape of pharmaceutical regulation necessitates a comprehensive understanding of post-approval changes (PAC), including the classifications of Post-Approval Supplements (PAS), Changes Being Effected in 30 Days (CBE-30), and Changes Being Effected Immediately (CBE-0). Regulatory professionals must adequately track, manage, and justify these changes across multiple jurisdictions, including the US, EU, and UK. This article serves as an exhaustive regulatory explainer manual to navigate the complexities of these processes and the expectations set forth by agencies such as…

Lifecycle planning to minimise the number of PAS filings over time Lifecycle planning to minimise the number of PAS filings over time Context In the pharmaceutical and biotechnology industries, regulatory affairs (RA) serves as the bridge between the company and the regulatory authorities, ensuring that products meet necessary requirements for safety, efficacy, and quality. A crucial aspect of RA is the management of post-approval changes (PAC), which includes the implementation of modifications to manufacturing processes, facilities, and controls after a product has been approved. This article focuses on understanding the various types of post-approval submissions, specifically the Difference Between Post-Approval…

Audit readiness of documentation supporting post approval change history Audit Readiness of Documentation Supporting Post Approval Change History Context In the pharmaceutical and biotech industries, Post Approval Changes (PAC) are modifications made to an approved drug product after it has received an authorization from the relevant regulatory authority. These changes can occur in various aspects, including manufacturing processes, quality control procedures, and labeling. Compliance with regulatory expectations for documenting and classifying these changes is critical for maintaining product integrity and regulatory approval. This article aims to provide a clear regulatory affairs explainer manual on the documentation and submission requirements associated…